Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

gy development effort and favorable

preclinical research results showing that 2ME2 has disease modifying or

"DMARD" activity, The FDA has accepted EntreMed's IND for 2ME2 in RA,

which included an extensive human safety dossier in 300 patients from

the oncology studies. Panzem(R) for RA represents a safe, orally

administered, small molecule alternative to current biologicals and a

potential "first-in-class" cross-over opportunity from oncology. The

Company plans to initiate a normal volunteer clinical trial in 2008

and seek a development partner to manage larger multi-arm Phase 2 and

Phase 3 studies.

EntreMed President & CEO, James S. Burns, commented, "We are concentrating our resources on fewer programs that we believe have greater potential for product registration and ultimately commercialization. We have three promising oncology programs to pursue in 2008: MKC-1 in multiple Phase 1 and 2 trials, ENMD-1198 that we expect to enter into Phase 2 before year end, and ENMD-2076 that will begin a Phase 1b clinical trial shortly, together with our initial clinical trial for Panzem(R) in a potentially larger RA market."

Mr. Burns further commented, "Our goal in 2008 is to continue moving ahead on priority programs while maintaining our cash expenditures at approximately the same level as in 2007. As part of our financial plan, we are also focusing increased attention on partnering one or more of our programs in order to fund and advance our programs into later stages of development. We will, however, continue to selectively seek opportunities such as individual products or companies that could favorably impact the quality of our pipeline, allow us to de-risk the Company, and enhance shareholder value."

A digital recording of the Company's will be available approximately two hours after the completion of the conference and will be accessible for 60 days. To access the rec
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... Miami, FL on March 10, 2015 ... , Chief Financial Officer, will provide a corporate overview. ... of Halozyme,s corporate website at www.halozyme.com , and a ... event. To access the live webcast, please log on to ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Gene Therapy Market, 2015 - 2025" report to ... 2015-2025" report provides an extensive study on the marketed ... been carried out in this field for over a ... available in Asian markets; one approved in the EU). ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3
... Abbott (NYSE: ABT ),will present at the Cowen ... 17, 2008. Thomas C. Freyman, executive vice president,finance and ... the,company at 10:30 a.m. Central time., A live ... Investor Relations Web site at http://www.abbottinvestor.com . An,archived ...
... March 7 DCI-Biolafitte, (http://www.dci-bio.com ), a ... bioreactors, control systems and software, will exhibit ... Convention Center in Philadelphia,March 26-28. DCI-Biolafitte will ... next generation of single-use bioreactors.,DCI-Biolafitte will display ...
... March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... commercializing proprietary product candidates principally,for use in the ... its,fourth quarter and full year ended December 31, ... Wednesday, March 12, 2008., Cadence management will ...
Cached Biology Technology:Biotechnology Leader to Exhibit at Upcoming Trade Show 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ... 2020. Also, a seven-year historic analysis is provided for these markets. ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2
... , Irvine, Calif., May 26, 2010 UC Irvine ... embryonic stem cells, the first three-dimensional tissue structure to ... the first step toward the development of transplant-ready retinas ... macular degeneration that affect millions. "We made a ...
... University have made an important fundamental advance in robotics, in ... walk and run effectively, but use little energy in the ... studies are moving closer to robots that could take on ... that work much better, or even help some people who ...
... at Northwestern University Feinberg School of Medicine have identified ... the smallest blood vessels remove blood clots and other ... mechanisms that may be involved in age-related cognitive decline, ... These findings were described in the May 27 issue ...
Cached Biology News:UCI researchers create retina from human embryonic stem cells 2Advances made in walking, running robots 2Advances made in walking, running robots 3Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... than 1500 known aptamer sequences. Add up ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
Biology Products: